NO20050127L - 9-alfa-substituerte ostratriener som selektivt aktive ostrogener - Google Patents

9-alfa-substituerte ostratriener som selektivt aktive ostrogener

Info

Publication number
NO20050127L
NO20050127L NO20050127A NO20050127A NO20050127L NO 20050127 L NO20050127 L NO 20050127L NO 20050127 A NO20050127 A NO 20050127A NO 20050127 A NO20050127 A NO 20050127A NO 20050127 L NO20050127 L NO 20050127L
Authority
NO
Norway
Prior art keywords
ostratrienes
oestrogens
alpha
substituted
selectively active
Prior art date
Application number
NO20050127A
Other languages
English (en)
Other versions
NO20050127D0 (no
NO329563B1 (no
Inventor
Karl-Heinrich Fritzemeier
Peter Muhn
Gerd Mueller
Dirk Kosemund
Alexander Hillisch
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20050127D0 publication Critical patent/NO20050127D0/no
Publication of NO20050127L publication Critical patent/NO20050127L/no
Publication of NO329563B1 publication Critical patent/NO329563B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0055Estrane derivatives not substituted in position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20050127A 2002-06-11 2005-01-10 9-alfa-substituerte ostratriener som selektivt aktive ostrogener, farmasoytiske preparater som inneholder forbindelsene, samt anvendelse derav til fremstilling av farmasoytiske midler NO329563B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
PCT/EP2003/006172 WO2003104253A2 (de) 2002-06-11 2003-06-11 9-alpha-substituierte estratriene als selektiv wirksame estrogene

Publications (3)

Publication Number Publication Date
NO20050127D0 NO20050127D0 (no) 2005-01-10
NO20050127L true NO20050127L (no) 2005-03-11
NO329563B1 NO329563B1 (no) 2010-11-15

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050127A NO329563B1 (no) 2002-06-11 2005-01-10 9-alfa-substituerte ostratriener som selektivt aktive ostrogener, farmasoytiske preparater som inneholder forbindelsene, samt anvendelse derav til fremstilling av farmasoytiske midler

Country Status (28)

Country Link
EP (1) EP1517914B1 (no)
JP (1) JP4615998B2 (no)
KR (1) KR101006612B1 (no)
CN (1) CN1293090C (no)
AR (1) AR040188A1 (no)
AT (1) ATE303397T1 (no)
AU (1) AU2003242683B9 (no)
BR (1) BR0312140A (no)
CA (1) CA2486495C (no)
CR (1) CR10289A (no)
CU (1) CU23414B7 (no)
DE (2) DE10226326A1 (no)
DK (1) DK1517914T3 (no)
EA (1) EA008442B1 (no)
EC (1) ECSP055530A (no)
ES (1) ES2248770T3 (no)
HR (1) HRP20050009B1 (no)
IL (1) IL165321A (no)
MX (1) MXPA04012491A (no)
NO (1) NO329563B1 (no)
PE (1) PE20040613A1 (no)
PL (1) PL209910B1 (no)
RS (1) RS50878B (no)
TW (1) TWI286140B (no)
UA (1) UA78062C2 (no)
UY (1) UY27844A1 (no)
WO (1) WO2003104253A2 (no)
ZA (1) ZA200500217B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
PT1689410E (pt) * 2003-11-26 2008-08-18 Bayer Schering Pharma Ag Prevenção e tratamento de doenças cardíacas hipertensivas pelos estrogénios selectivos 8beta-vinil-estra-1,3,5(10)-trieno-3,17beta-diol e 17beta-fluoro-9alfa-vinil-estra-1,3,5(10)-trieno-3,16alfa-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US20110052699A1 (en) * 2008-02-13 2011-03-03 Adrian Funke Drug delivery system with stabilising effect
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
JP2012509286A (ja) * 2008-11-21 2012-04-19 バイエル ファーマ アクチエンゲゼルシャフト 薬物送達システム
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
WO2020051329A1 (en) * 2018-09-07 2020-03-12 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
EP1226155B1 (de) * 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroide als selektiv wirksame estrogene
SK14632002A3 (sk) * 2000-04-12 2003-03-04 Schering Aktiengesellschaft Substituované estratriény a ich použitie ako selektívne účinných estrogénov

Also Published As

Publication number Publication date
ATE303397T1 (de) 2005-09-15
HRP20050009A2 (en) 2005-04-30
ECSP055530A (es) 2005-03-10
UA78062C2 (en) 2007-02-15
CA2486495A1 (en) 2003-12-18
HRP20050009B1 (hr) 2013-07-31
WO2003104253A2 (de) 2003-12-18
CU23414B7 (es) 2009-09-08
EA008442B1 (ru) 2007-06-29
WO2003104253A3 (de) 2004-09-16
NO20050127D0 (no) 2005-01-10
EP1517914B1 (de) 2005-08-31
DE50301116D1 (de) 2005-10-06
MXPA04012491A (es) 2005-06-08
BR0312140A (pt) 2005-04-05
JP4615998B2 (ja) 2011-01-19
RS50878B (sr) 2010-08-31
KR20050009745A (ko) 2005-01-25
CA2486495C (en) 2011-04-19
PL373090A1 (en) 2005-08-08
AU2003242683A1 (en) 2003-12-22
AR040188A1 (es) 2005-03-16
PL209910B1 (pl) 2011-11-30
JP2005533053A (ja) 2005-11-04
AU2003242683B9 (en) 2009-08-27
EA200401544A1 (ru) 2005-06-30
KR101006612B1 (ko) 2011-01-10
HK1081203A1 (en) 2006-05-12
CR10289A (es) 2008-11-26
TWI286140B (en) 2007-09-01
CN1659181A (zh) 2005-08-24
CN1293090C (zh) 2007-01-03
EP1517914A2 (de) 2005-03-30
PE20040613A1 (es) 2004-12-01
RS107004A (sr) 2006-10-27
UY27844A1 (es) 2003-12-31
IL165321A (en) 2009-08-03
TW200407331A (en) 2004-05-16
ZA200500217B (en) 2006-03-29
DK1517914T3 (da) 2006-01-16
ES2248770T3 (es) 2006-03-16
NO329563B1 (no) 2010-11-15
DE10226326A1 (de) 2004-01-15
AU2003242683B2 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
NO2017069I1 (no) Besponsa
DK3473251T3 (da) Nikotin-cellulose-kombination
DE60333919D1 (de) Spiroindolinpiperidinderivate
DE60328309D1 (de) Ssigkeiten
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
NO20052802D0 (no) Pyrrolopyrimidinderivativer
NO20044613L (no) Indolylmaleimidderivater
EP1539332A4 (en) IONIZATION SOURCE WITH MULTIPLE MODES
ATE427876T1 (de) Luftkissenboot
ATE318817T1 (de) Aza-arylpiperazine
NO20044007L (no) Skjaerelokaliseringsverktoy
ATE349458T1 (de) Etonogestrelester
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
ATA1572002A (de) Managementspleisskassette
NO20050127D0 (no) 9-alfa-substituerte ostratriener som selektivt aktive ostrogener
FI20021957A0 (fi) Lipeäruisku
ATA4142004A (de) Trägerverbau
NO20043664L (no) Ny fremgangsmate
ATE469773T1 (de) Zugöse
ATA19152002A (de) Hubkupplung
DE60205924D1 (de) Mikrogreifer
ITMI20021327A1 (it) Nuove ossialchilpiperazine
ATE396192T1 (de) N-sulfonylaminothiazole
FR2840006B1 (fr) Construction demontable
DE10244834B8 (de) Suszeptometer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

MM1K Lapsed by not paying the annual fees